Effect of bisphosphonates in preventing femoral periprosthetic bone resorption after primary cementless total hip arthroplasty: a meta-analysis

Xinyu Zhao, Dongcai Hu, Jun Qin, Rahul Mohanan and Liaobin Chen*

Abstract
Background: Bone loss leading to aseptic loosening of the prosthesis and periprosthetic fracture is a mode of failure in cementless total hip arthroplasty (THA). The aim of this meta-analysis was to evaluate the effect of bisphosphonates in preventing femoral periprosthetic bone resorption following primary cementless THA zone by zone.

Method: Clinical randomized controlled trials concerning bisphosphonates application after primary cementless THA published up to October 2014 were retrieved from PubMed, Cochrane library, and Embase databases. The methodological quality of the included studies was assessed by the Physiotherapy Evidence Database (PEDro) scale. Data analysis was performed using StataSE12.0.

Results: Ten randomized controlled trials involving a total of 502 patients were assessed; the bisphosphonates group included 256 patients and the control group included 246 patients. The meta-analysis showed that the bone mineral density (BMD) of most femoral periprosthetic zones in bisphosphonates group was significantly higher than that in the control group at 3 months postoperatively except zone 5 with no significant difference. At 6 and 12 months, the BMD of bisphosphonates group was much higher than that in control group except zone 5, which showed no statistical difference. The BMD of bisphosphonates group was persistently higher than control group in zone 6 and 7 at 5 years postoperatively, while the other zones had no significant difference. Both serum bone alkaline phosphatase and urinary type I collagen N-telopeptide were significantly suppressed by bisphosphonates at 3, 6, and 12 months.

Conclusion: Bisphosphonates seem to decrease early femoral periprosthetic bone resorption after primary cementless THA. Drug efficacy was found to be long-standing in the main load-bearing zones.

Keywords: Total hip arthroplasty, Bisphosphonate, Bone mineral density, Meta-analysis

Background
Total hip arthroplasty (THA) is an effective treatment for end-stage avascular necrosis of femoral head, osteoarthritis, and rheumatoid arthritis of the hip [1]. By 2030, the demand for primary THA is estimated to reach 572,000, and the demand for hip revision is estimated to double in the USA [2]. Some studies indicated that more than 75% of the revision arthroplasties were performed for aseptic loosening of the prosthesis and periprosthetic fracture, which were all found to be the sequel to severe periprosthetic bone loss [3].

Bisphosphonates are effective antiresorptive agents which have been used successfully to treat diseases characterized by osteoclast-mediated bone resorption, such as osteoporosis, Paget disease, and metastatic bone diseases [4]. Recently, several randomized controlled trials (RCTs) were performed to investigate the effect of bisphosphonates on femoral periprosthetic bone resorption following primary THA, most of which confirmed its efficacy, while some doubted it [5-7]. Two systematic reviews [8, 9] suggested that bisphosphonates have a beneficial effect on preserving periprosthetic bone in a short term after joint arthroplasty, while they had some limitations: (1) They ignored the fundamental difference between cement and cementless arthroplasty and did...
not describe it separately; The systematic reviews also included patients who underwent hemiarthroplasty and total knee arthroplasty and (2) They did not describe the periprosthetic bone loss zone by zone as they overlooked the uneven effect of bisphosphonates induced on different load-bearing areas of periprosthetic bone.

Therefore, we divided the femoral periprosthetic bone stock into seven regions of interest (ROI) as described by Gruen [10] (Fig. 1). We extracted the data of bone mineral density (BMD) from each included RCT, studying the effects of bisphosphonates in preventing femoral periprosthetic bone resorption following primary cementless THA. Serum bone alkaline phosphatase (BAP) and urinary type I collagen N-telopeptide breakdown products (NTX) were added as indices for the resorption. We performed the meta-analysis to clarify the effect of bisphosphonates in the treatment of periprosthetic bone resorption after cementless THA.

Methods
Search strategy
The PubMed, Embase, and Cochrane Central Register of Controlled Trials were searched from their earliest entries through October 2014. The search strategy was (((random*[Title/Abstract]) OR "Randomized Controlled Trial" [Publication Type])) AND (((hip arthroplasty [Title/Abstract]) OR hip replacement [Title/Abstract]) OR hip prosthesis [Title/Abstract]) OR "Arthroplasty, Replacement, Hip" [Mesh]) AND (((((risoledronate [Title/Abstract]) OR tiludronate [Title/Abstract]) OR alendronate [Title/Abstract]) OR pamidronate [Title/Abstract]) OR etidronate [Title/Abstract]) OR zoledronate [Title/Abstract]) OR clodronate [Title/Abstract]) OR Bisphosphonate [Title/Abstract]). The reference list of the relevant literatures was also reviewed manually for any further relevant studies. Languages were not restricted in this search.

Inclusion criteria and exclusion criteria
Inclusion criteria were as follows: (1) the target population consisted of patients undergoing primary cementless THA; (2) in the interventional group, the administration of the bisphosphonate group was oral, intramuscular, or intravenous, while the control group had been treated with calcium, alfacalcidol, or no medication; (3) the outcomes were analyzed with respect to BMD, serum BAP, and urinary NTX; and (4) the methodological criterion was prospective RCT.

Exclusion criteria were (1) cemented THA or other arthroplasties and (2) animal studies.

Data extraction and assessment of methodological quality
After the consecutive procedures of screening of titles and abstracts, obtaining the full text of each article, and reviewing them, articles that met the eligibility criteria and did not meet the exclusion criteria were selected to be included. Data were extracted and collated independently by two authors (XYZ and DCH), including author, published year, sample size, patient age, sex, follow-up time, intervention protocol, BMD of each ROI in femoral periprosthetic bone, serum BAP, and urinary NTX. The data of a published updated study involving the same cohort of patients was extracted synthetically. The original investigators were contacted when requisite data were lacking in the publications. The methodological quality of each included RCT was assessed by two observers independently by the Physiotherapy Evidence Database (PEDro) scale [11], and trials with a score of 6 or more were considered high quality. Disagreements were resolved by means of discussion with the corresponding author (LBC).

Statistical methods
The meta-analysis was conducted with StataSE12.0 software. The weighted mean difference (WMD) and 95% confidence interval (CI) were calculated for continuous data, and the relative risk (RR) and 95% CI were calculated for dichotomous data. The statistical heterogeneity was tested with the chi-square test and $I^2$. If heterogeneity was low ($P > 0.1, I^2 < 50\%$), a fixed-
If heterogeneity was significant ($P < 0.1$, $I^2 > 50\%$), sensitivity analysis, subgroup analyses, and meta-regression were conducted to find the source of the heterogeneity. If the heterogeneity could not be eliminated, a random-effect model would be used when the result of meta-analysis had clinical homogeneity, or descriptive analysis would be used.

**Results**

**Study characteristics**

A total of 96 potential articles were identified and screened for the meta-analysis. After screening of titles and abstracts, obtaining the full text of each article, and reviewing them, ten RCTs were selected for this meta-analysis [7, 12-20] (Fig. 2). The cumulative sample size of 502 primary cementless THA comprised 256 with bisphosphonates and 246 without bisphosphonates. The main characteristics of the included studies were summarized in Table 1 and the literature-exclusion procedure was depicted in Fig. 2. The methodological quality of the included RCTs was assessed with the PEDro scale (Table 2), the results showed that all RCTs were of high quality.

The BMD was assessed by the method of dual-energy X-ray absorptiometry in all the included RCTs. The changes of BMD in femoral periprosthetic ROI at 3 months after surgery were reported in four [12, 13, 16, 17] of the ten studies. The results of meta-analysis of some ROI appeared heterogeneous, and sensitivity analysis indicated that the heterogeneity came from the studies of Skoldenberg et al. [13] and Trevisan et al. [17]. Subgroup analyses failed to eliminate the heterogeneity, then we found that, regardless of the exclusion or inclusion of these two studies, the results of meta-analysis were all the same and had clinical agreement, so we included these two studies and conducted the meta-analysis by random-effect model for the reason that these two studies were of high quality. Meta-analysis indicated that BMD ratios in the bisphosphonates group were significantly higher than those in the control group mainly in zones 1, 2, 3, 4, 6, and 7 ($P < 0.05$), while lower in zone 5 ($WMD = -0.619$, 95% CI: $-1.120$ ~ $-0.119$, $P < 0.015$, Table 3).

The changes of BMD in femoral periprosthetic ROI at 6 months after surgery were reported in eight [7, 12-17, 19-20] of the ten studies. The results of meta-analysis of some ROI appeared heterogeneous, and sensitivity analysis indicated that the heterogeneity came from the studies of Skoldenberg et al. [13] and Trevisan et al. [17]. Subgroup analyses failed to eliminate the heterogeneity, then we found that, regardless of the exclusion or inclusion of these two studies, the results of meta-analysis were all the same and had clinical agreement, so we included these two studies and conducted the meta-analysis by random-effect model for the reason that these two studies were of high quality. Meta-analysis indicated that BMD ratios in the bisphosphonates group were significantly higher than those in the control group mainly in zones 1, 2, 3, 4, 6, and 7 ($P < 0.05$), while lower in zone 5 ($WMD = -0.619$, 95% CI: $-1.120$ ~ $-0.119$, $P < 0.015$, Table 3).

The changes of BMD in femoral periprosthetic ROI at 6 months after surgery were reported in eight [7, 12-17, 19-20] of the ten studies. The results of meta-analysis of some ROI appeared heterogeneous, and sensitivity analysis indicated that the heterogeneity came from the studies of Skoldenberg et al. [13] and Trevisan et al. [17]. Subgroup analyses failed to eliminate the heterogeneity, then we found that, regardless of the exclusion or inclusion of these two studies, the results of meta-analysis were all the same and had clinical agreement, so we included these two studies and conducted the meta-analysis by random-effect model for the reason that these two studies were of high quality. Meta-analysis indicated that BMD ratios in the bisphosphonates group were significantly higher than those in the control group mainly in zones 1, 2, 3, 4, 6, and 7 ($P < 0.05$), while lower in zone 5 ($WMD = -0.619$, 95% CI: $-1.120$ ~ $-0.119$, $P < 0.015$, Table 3).

### Fig. 2 Flow chart summarizing the selection process of randomized control trials
of the ten studies. Heterogeneity was analyzed through the same method, and random-effect model would be used if necessary. The pooling result showed that the BMD of the bisphosphonates group in most zones were significantly higher than that of the control group ($P < 0.05$, Table 4) except no statistical difference of

Six papers [12, 13, 15, 17, 19, 20] described the post-operative BMD ratios at 12 months, and the same procedure of analysis was performed. The Forest plots also indicated that the BMD of the bisphosphonates group were significantly higher ($P < 0.05$, Table 5) than that of the control group except zone 5 with no statistical difference ($P = 0.696$, Table 5).

The postoperative BMD ratios at 5 years after surgery were calculated in two studies [7, 19], and fixed-effect model was used in all zones as no heterogeneity was detected. The results of meta-analysis showed that BMD of the bisphosphonates group in zones 6 and 7 were significantly higher ($P < 0.05$) than that of the control group, while no statistical difference were found in the rest of the zones ($P > 0.05$, Table 6).

Serum bone alkaline phosphates
Two papers [17, 18] including 71 patients in the bisphosphonates group and 69 patients in the control group described the postoperative serum BAP at 3 months, fixed-effect model was used as heterogeneity was not detected ($P = 0.222$, $I^2 = 33$). The pooling result showed the serum BAP in the bisphosphonates group was significantly lower than that of the control group

| Author    | Year of publication | Follow-up time (months) | Sample size | Patient mean age (years) | Sex | Bisphosphonates/ control group | Intervention protocol |
|-----------|---------------------|-------------------------|-------------|--------------------------|-----|-------------------------------|-----------------------|
| Hennigs T | 2002                | 12                      | 66          | 51.5                     | 29/27 | 42/24 | Subgroup 1: oral alendronate 10 mg/day for 10 weeks |
|           |                     |                         |             |                          |      |                                | Subgroup 2: oral alendronate 20 mg/day for 5 weeks |
| Arabmotlagh M | 2006          | 72                      | 51          | 62.5                     | 26/25 | 27/24 | Subgroup 1: oral alendronate 20 mg/day for 2 months, thereafter 20 mg/day for 4 months |
|           |                     |                         |             |                          |      |                                | Subgroup 2: oral alendronate 20 mg/day for 2 months, thereafter 20 mg/day for 6 months |
| Arabmotlagh M | 2009          | 72                      | 49          | 62.5                     | 25/24 | 29/20 | Subgroup 1: oral alendronate 10 mg/day for 10 weeks |
|           |                     |                         |             |                          |      |                                | Subgroup 2: oral alendronate 20 mg/day for 5 weeks |
| Iwamoto N | 2011                | 12                      | 60          | 65                       | 14/46 | 20/40 | Oral alendronate 5 mg/day for 48 weeks |
| Skoldenberg OG | 2011        | 24                      | 73          | 60                       | 30/43 | 36/37 | Oral risedronate 35 mg/week for 6 months |
| Tapaninen TS | 2010           | 60                      | 16          | 61.4                     | 7/9   | 7/9   | Oral alendronate 10 mg/day for 6 months |
| Trevisan C | 2010                | 12                      | 91          | 64.7                     | 53/58 | 42/49 | Oral clodronate 100 mg/day for 10 days, thereafter 100 mg/week for 50 weeks |
| Venesmaa PK | 2001              | 6                       | 13          | 62.62                    | 6/7   | 8/5   | Oral alendronate 10 mg/day for 6 months |
| Yamaguchi K | 2005              | 12                      | 43          | 68.5                     | 0/44  | 26/17 | Oral etidronate 200 mg/day for 2 weeks, followed by 12 weeks of calcium lactate of 500 mg/day, the cycle was repeated four times |
|           |                     |                         |             |                          |      |                                | Subgroup 2: oral etidronate 400 mg/day for 2 weeks, followed by 12 weeks of calcium lactate of 500 mg/day, the cycle was repeated four times |
| Yamasaki S | 2007                | 6                       | 40          | 66.7                     | 4/36  | 19/21 | Oral risedronate 2.5 mg/week for 6 months |

Table 1 Details on the included studies in the meta-analysis

| Author    | Year of publication | Follow-up time (months) | Sample size | Patient mean age (years) | Sex | Bisphosphonates/ control group | Intervention protocol |
|-----------|---------------------|-------------------------|-------------|--------------------------|-----|-------------------------------|-----------------------|
| Hennigs T | 2002                | 12                      | 66          | 51.5                     | 29/27 | 42/24 | Subgroup 1: oral alendronate 10 mg/day for 10 weeks |
|           |                     |                         |             |                          |      |                                | Subgroup 2: oral alendronate 20 mg/day for 5 weeks |
| Arabmotlagh M | 2006          | 72                      | 51          | 62.5                     | 26/25 | 27/24 | Subgroup 1: oral alendronate 20 mg/day for 2 months, thereafter 20 mg/day for 4 months |
|           |                     |                         |             |                          |      |                                | Subgroup 2: oral alendronate 20 mg/day for 2 months, thereafter 20 mg/day for 6 months |
| Arabmotlagh M | 2009          | 72                      | 49          | 62.5                     | 25/24 | 29/20 | Subgroup 1: oral alendronate 10 mg/day for 10 weeks |
|           |                     |                         |             |                          |      |                                | Subgroup 2: oral alendronate 20 mg/day for 5 weeks |
| Iwamoto N | 2011                | 12                      | 60          | 65                       | 14/46 | 20/40 | Oral alendronate 5 mg/day for 48 weeks |
| Skoldenberg OG | 2011        | 24                      | 73          | 60                       | 30/43 | 36/37 | Oral risedronate 35 mg/week for 6 months |
| Tapaninen TS | 2010           | 60                      | 16          | 61.4                     | 7/9   | 7/9   | Oral alendronate 10 mg/day for 6 months |
| Trevisan C | 2010                | 12                      | 91          | 64.7                     | 53/58 | 42/49 | Oral clodronate 100 mg/day for 10 days, thereafter 100 mg/week for 50 weeks |
| Venesmaa PK | 2001              | 6                       | 13          | 62.62                    | 6/7   | 8/5   | Oral alendronate 10 mg/day for 6 months |
| Yamaguchi K | 2005              | 12                      | 43          | 68.5                     | 0/44  | 26/17 | Oral etidronate 200 mg/day for 2 weeks, followed by 12 weeks of calcium lactate of 500 mg/day, the cycle was repeated four times |
|           |                     |                         |             |                          |      |                                | Subgroup 2: oral etidronate 400 mg/day for 2 weeks, followed by 12 weeks of calcium lactate of 500 mg/day, the cycle was repeated four times |
| Yamasaki S | 2007                | 6                       | 40          | 66.7                     | 4/36  | 19/21 | Oral risedronate 2.5 mg/week for 6 months |

Table 2 PEDro critical appraisal scores

| Author    | PEDro critical appraisal score Total |
|-----------|-------------------------------------|
| Hennigs T | 2002 Y Y Y Y Y Y N Y Y Y Y Y Y Y Y 9 |
| Arabmotlagh M | 2006 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 9 |
| Arabmotlagh M | 2009 Y Y Y Y Y Y N Y Y Y Y Y Y Y Y 9 |
| Iwamoto N 2011 | Y Y Y Y Y Y N Y Y Y Y Y Y Y Y 8 |
| Skoldenberg OG | 2011 Y Y Y Y Y Y N Y Y Y Y Y Y Y Y 9 |
| Tapaninen TS 2010 | Y Y N Y N N N Y Y Y Y Y Y Y Y 6 |
| Trevisan C 2010 | Y Y N Y N N N Y Y Y Y Y Y Y Y 6 |
| Venesmaa PK 2001 | Y Y Y Y N N N N Y Y Y Y Y Y Y 7 |
| Yamaguchi K 2005 | Y Y N Y N N N Y Y Y Y Y Y Y Y 6 |
| Yamasaki S 2007 | Y Y N Y N N N Y Y Y Y Y Y Y Y 7 |

PEDro criteria: (1) eligibility criteria, (2) random allocation, (3) concealed allocation, (4) baseline comparability, (5) participant blinding, (6) therapist blinding, (7) assessor blinding, (8) >85 % follow-up, (9) intention-to-treat analysis, (10) between-groups statistical comparison for at least one key outcome, and (11) point estimates and variability measures for at least one key outcome. A trial with a score of 6 or more was considered high quality.
(WMD = −6.924, 95 % CI: −9.934 ~ −3.913, \( P = 0.001 \), Fig. 3).

The serum BAP at 6 months after surgery was reported in four [14, 15, 17, 18] of the ten studies, including 116 patients in the bisphosphonates group and 107 patients in the control group, and the same procedure of analysis was performed and random-effect model was used (\( P = 0.049, I^2 = 61.9 \% \)). The results of meta-analysis indicated that serum BAP of the bisphosphonates group was significantly lower than that of the control group (WMD = −5.874, 95 % CI: −8.332 ~ −3.416, \( P = 0.001 \), Fig. 4).

Three studies [15, 17, 18] including 95 patients in the bisphosphonates group and 86 patients in the control group described the postoperative serum BAP at 12 months. The Forest plots of fixed-effect model (\( P = 0.683, I^2 = 0 \% \)) also indicated that serum BAP of the bisphosphonates group was significantly lower than that of the control group (WMD = −3.395, 95 % CI: −6.171 ~ −0.619, \( P = 0.017 \), Fig. 5).

Yamasaki et al. [14] reported that the urinary NTX in the bisphosphonates group at 12 months after surgery was lower than that of the control group.

### Table 3: Comparison of postoperative BMD ratios at 3 months between each group

| ROI | BMD ratios in the bisphosphonates group | BMD ratios in the control group | WMD [95 % CI] | \( P \) of chi-square | \( I^2 \) | Selected model | \( P \) for overall effect |
|-----|-----------------------------------------|---------------------------------|---------------|------------------------|------|----------------|------------------------|
| 1   | 97.556                                  | 90.840                          | 6.364         | 2.122                  | 10.606 | 92 % Random-effect model | 0.003                  |
| 2   | 96.275                                  | 93.488                          | 2.479         | 1.886                  | 3.072  | 0.564          | 0 % Fixed-effect model | <0.001                 |
| 3   | 97.041                                  | 95.413                          | 1.309         | 0.824                  | 1.794  | 0.673          | 0 % Fixed-effect model | <0.001                 |
| 4   | 100.207                                 | 98.036                          | 2.349         | 0.505                  | 4.193  | 0.003          | 78 % Random-effect model | 0.013                  |
| 5   | 97.528                                  | 97.172                          | −0.619        | −1.120                 | −0.119 | 0.138          | 46 % Fixed-effect model | 0.015                  |
| 6   | 95.641                                  | 92.724                          | 2.177         | 1.598                  | 2.756  | 0.552          | 0 % Fixed-effect model | <0.001                 |
| 7   | 91.099                                  | 84.457                          | 6.634         | 0.655                  | 12.612 | 0.001          | 95 % Random-effect model | 0.030                  |

### Table 4: Comparison of postoperative BMD ratios at 6 months between each group

| ROI | BMD ratios in the bisphosphonates group | BMD ratios in the control group | WMD [95 % CI] | \( P \) of chi-square | \( I^2 \) | Selected model | \( P \) for overall effect |
|-----|-----------------------------------------|---------------------------------|---------------|------------------------|------|----------------|------------------------|
| 1   | 98.035                                  | 89.227                          | 8.422         | 4.313                  | 12.531 | 0.001          | 88 % Random-effect model | <0.001                 |
| 2   | 97.881                                  | 93.224                          | 4.142         | 0.611                  | 7.672  | 0.001          | 85 % Random-effect model | 0.021                  |
| 3   | 97.974                                  | 95.954                          | 1.930         | 0.668                  | 3.193  | 0.041          | 52 % Random-effect model | 0.003                  |
| 4   | 99.810                                  | 98.305                          | 1.357         | 0.188                  | 2.525  | 0.039          | 53 % Random-effect model | 0.023                  |
| 5   | 99.638                                  | 98.188                          | 0.564         | −0.855                 | 1.983  | 0.015          | 59 % Random-effect model | 0.436                  |
| 6   | 96.283                                  | 92.148                          | 3.863         | 1.291                  | 6.435  | 0.001          | 80 % Random-effect model | 0.003                  |
| 7   | 87.788                                  | 79.417                          | 8.371         | 4.239                  | 12.503 | 0.001          | 86 % Random-effect model | <0.001                 |

**Urinary type I collagen N-telopeptide**

The urinary NTX at 6 months after surgery was reported in two [14, 15] of the ten studies, including 45 patients in the bisphosphonates group and 38 patients in the control group, and random-effect model was used (\( P = 0.049, I^2 = 61.9 \% \)). The pooling result indicated that urinary NTX of the bisphosphonates group was significantly lower than that of the control group (WMD = −22.929, 95 % CI: −39.098 ~ −6.760, \( P = 0.005 \), Fig. 6).

Yamasaki et al. [14] reported that the urinary NTX in the bisphosphonates group at 12 months after surgery was lower than that of the control group.
Discussion

THA is an effective treatment for end-stage hip disease, but the aseptic loosening of implants and the periprosthetic fracture secondary to periprosthetic bone loss remain an unresolved problem. Three mechanisms are thought to contribute to femoral periprosthetic bone resorption [21]. (1) The intraoperative mechanical, thermal, and chemical damage cause necrosis in bone stock of variable size. It might take approximately 3 months to heal; (2) Delayed bone resorption process called 'stress shielding' occurs in proximal regions of the femur, which is related to the biomechanical characteristics of the bone-implant structure and the difference in stiffness of the prosthesis compared to the surrounding bone. Stress shielding tends to stabilize by 1 year postoperatively. (3) The inflammatory response caused by the detritus produced by the wear and tear of prosthesis is another reason for osteolysis, which mainly happens 5 years after surgery. If an ideal drug suppressing the bone resorption after THA was found, the service life of prosthesis would be much prolonged by maintaining BMD around it [21]. The antiresorptive effect of bisphosphonate is cell mediated, mainly by direct inhibitory effect on osteoclastic recruitment [18, 21, 22]. For patients after THA, the administration of bisphosphonates may decrease the risk of future hip fractures, reduce the chances of subsidence of the stem, lower the risk of revision, and prolong the survival time of prosthesis; however, some studies still doubt its long-term efficacy [13, 23-25].

The results of our meta-analysis indicated that the periprosthetic BMD in the bisphosphonate group was higher than that of the control group in most areas at 3, 6, and 12 months postoperatively. This effect seemed to persist in the main load-bearing areas of zones 6 and 7 at 5 years postoperatively. These results suggest that bisphosphonates decrease early femoral periprosthetic bone resorption after primary cementless THA and their efficacy are long-standing in the main load-bearing zones. Then, we discussed the

| Table 5 | Comparison of postoperative BMD ratios at 12 months between each group |
|---------|--------------------------------------------------|
| ROI     | BMD ratios in bisphosphonates | BMD ratios in control group | WMD [95 % CI] | \( P \) of chi-square | \( I^2 \) | Selected model | \( P \) for overall effect |
| 1       | 96.005                           | 87.601                       | 6.819         | 3.816               | 9.821      | 0.009         | Random-effect model      | <0.001 |
| 2       | 99.032                           | 92.431                       | 6.250         | 5.314               | 7.186      | 0.386         | Fixed-effect model       | <0.001 |
| 3       | 99.786                           | 97.172                       | 2.822         | 0.615               | 5.029      | 0.001         | Random-effect model      | 0.012  |
| 4       | 101.002                          | 98.085                       | 2.540         | 0.948               | 4.132      | 0.002         | Random-effect model      | 0.002  |
| 5       | 101.189                          | 100.601                      | -0.303        | -1.823              | 1.218      | 0.074         | Fixed-effect model       | 0.696  |
| 6       | 97.458                           | 91.817                       | 5.220         | 3.262               | 7.178      | 0.018         | Random-effect model      | <0.001 |
| 7       | 85.797                           | 77.128                       | 8.153         | 5.130               | 11.175     | 0.002         | Random-effect model      | <0.001 |

| Table 6 | Comparison of postoperative BMD ratios at 5 years between each group |
|---------|--------------------------------------------------|
| ROI     | BMD ratios in bisphosphonates | BMD ratios in control group | WMD [95 % CI] | \( P \) of chi-square | \( I^2 \) | Selected model | \( P \) for overall effect |
| 1       | 98.301                           | 93.225                       | 3.113         | -7.234              | 13.461     | 0.364         | Fixed-effect model       | 0.555  |
| 2       | 95.222                           | 93.382                       | -0.391        | -6.359              | 5.578      | 0.387         | Fixed-effect model       | 0.898  |
| 3       | 95.092                           | 96.161                       | -2.885        | -6.893              | 1.123      | 0.508         | Fixed-effect model       | 0.158  |
| 4       | 95.685                           | 96.943                       | -2.756        | -6.559              | 1.047      | 0.640         | Fixed-effect model       | 0.155  |
| 5       | 95.570                           | 96.829                       | -1.618        | -5.633              | 2.398      | 0.750         | Fixed-effect model       | 0.430  |
| 6       | 98.976                           | 92.007                       | 7.002         | 0.004               | 14.001     | 0.925         | Fixed-effect model       | 0.050  |
| 7       | 79.444                           | 69.561                       | 9.664         | 1.754               | 17.575     | 0.852         | Fixed-effect model       | 0.017  |
changes of BMD combined with the alterations of biomechanical characteristic in the proximal-medial area of the femur after THA. The normal mechanical loading in proximal femur starts in zone 7, then goes down to the cortical bone of zone 6. After turning to zone 3, the mechanical loading will continue downward. The cortical bone of zones 1 and 2 also shares part of the loading. After THA, the stress shielding will cause significant decrease in load bearing in zones 1, 2, 3, 6, and 7. However, the load bearing in zone 5 does not change apparently [26, 27]. In our study, the pooling results at 3 months after surgery indicated the BMD of the bisphosphonates group was all significantly higher than that of the control group except zone 5. The reason for this phenomenon might be that the bone resorption due to stress shielding was significantly suppressed by bisphosphonates in most zones; however, stress shielding is not apparent in zone 5, which limits the antiresorptive efficacy of bisphosphonates [26, 27]. As the accumulation of bone formation, no difference was detected in zone 5 at 6 and 12 month after surgery. After 3 months, the reconstruction of the intraoperative bone damage has finished and the bone resorption induced by stress shielding becomes the leading effect [12, 13, 19, 28], so the BMD in the bisphosphonates group were found to be higher than that of the control group except zone 5. At the fifth postoperative year, by pooling the results of the existing studies, we found that the BMD of the main load-bearing zones 6 and 7 in the bisphosphonates group was still higher than that of the control group, which suggests that the efficacy of limited course of bisphosphonates in the existing studies are long-standing in the main load-bearing zones.

The results of our meta-analysis showed that the serum BAP and urinary NTX were suppressed by...
bisphosphonates in postoperative 1 year, which also proves the antiresorptive efficacy of bisphosphonates from metabolic level.

Only one of our included studies had a course of bisphosphonates lasting for 1 year, the rest were all less than 6 months, and all follow-up were less than 6 years. Eberhardt et al. [29] reported that postoperative continuous and high-dose bisphosphonate treatment is potent in accelerating osseointegration of the prosthesis, which may prevent wear debris from migration by sealing the implant-bone interface. However, the efficacy of bisphosphonates on this phenomenon needs further research as the limited course of treatment and follow-up in our study. The current studies suggest that the timing of the administration of bisphosphonate may be related to its efficacy [6, 16, 18]; a long-term administration of bisphosphonate is well tolerated and can increase BMD remarkably [30]. Considering that bone loss around the prosthesis of THA is suspected to be progressive and faster than that due to normal aging, Skoldenberg et al. [13] suggested that the duration of bisphosphonate treatment should be lifelong to achieve a reduced risk of revision and an improved quality of life; however, this hypothesis needs further research.

The limitations of our study include the following. (1) The BMD results of meta-analysis of some ROI appeared heterogeneous, and sensitivity analysis and subgroup analyses failed to eliminate the heterogeneity. As those results of meta-analysis had clinical agreement, we included those studies and conducted the meta-analysis by random-effect model for the reason that those studies were of high quality, which may slightly influence the reliability of the meta-analysis. (2) The included studies did not have sufficient duration of bisphosphonate treatment and follow-up, and they also lacked evaluating indexes like functional scores and the rate of revision, so we could not evaluate the efficacy of postoperative bisphosphonate treatment comprehensively.

**Conclusion**

Bisphosphonates seem to decrease early femoral peri-prosthetic bone resorption after primary cementless THA, their efficacy are long-standing in the main
load-bearing zones. Considering the conclusions of other researches and the fact that most of our included studies just had a course of bisphosphonates treatment for less than 6 months, the long-term effects should be evaluated by new RCTs, which should be performed with a longer duration of bisphosphonates administration and follow-up to clarify the best dosage and duration of bisphosphonates treatment.

Abbreviations

THA: Total hip arthroplasty; PEDro: Physiotherapy Evidence Database; BMD: Bone mineral density; RCTs: Randomized controlled trials; ROIs: Regions of interest; BAP: Bone alkaline phosphatase; NTx: Urinary type I collagen Ntelopeptide breakdown products; WMD: Weighted mean difference; CI: Confidence interval.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

XYZ carried out the entire procedure including the literature search and data extraction. He performed the statistical analysis, drafted the manuscript, and revised the submitted the manuscript. LBC conceived of the study, coordinated and participated in the entire process of drafting, and revised the manuscript. DCH contributed to statistical analysis and revision of the manuscript. JQ and RM contributed to the revisions of the manuscript. All authors have contributed significantly. All authors read and approved the final manuscript.

Acknowledgements

The authors thank Jingfeng Li for his expert technical assistance and He Xiao for his expert statistical assistance.

Source of funding

No external funding was received in support of this study.

Received: 12 January 2015 Accepted: 15 April 2015

Published online: 13 May 2015

References

1. Mednick RE, Ahl HM, Krishnan V, Loevechio F, Manning DW. Factors affecting readmission rates following primary total hip arthroplasty. J Bone Joint Surg Am. 2014;96(2):120–9.
2. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and readmission rates following primary total hip arthroplasty. J Bone Joint Surg Am. 2007;89:780–5.
3. Fokter SK, Komadina R, Repse-Fokter A. Effect of etidronate in preventing radiological outcome of total hip replacement five years after pamidronate therapy. A trial extension. J Bone Joint Surg Br. 2006:83:579–86.
4. Morris CD, Einhorn TA. Bisphosphonates in orthopaedic surgery. J Bone Joint Surg Am. 2005;87:1609–18.
5. Fokter SK, Komadina R, Repse-Fokter A. Effect of etidronate in preventing postprosthetic bone loss following cemented hip arthroplasty: a randomized, double-blind, controlled trial. Wien Klin Wochenschr. 2006;118 Suppl 2:23–8.
6. Shetty N, Hamer AJ, Stockley I, Eastell R, Wilkinson JM. Clinical and radiological outcome of total hip replacement five years after pamidronate therapy. A trial extension. J Bone Joint Surg Br. 2006:88:1309–15.
7. Tapaninen TS, Vennema PP, Junvelin JS, Miettinen HJ, Kroger HP. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty - a 5-year follow-up of 16 patients. Scand J Surg. 2010;99:32–7.
8. Bhandari M, Bajjaran S, Guyatt GH, Griffith L, Busse MW, Schunemann HJ, et al. Effect of bisphosphonates on periprosthetic bone mineral density after total joint arthroplasty: A meta-analysis. J Bone Joint Surg Am. 2005;87:293–301.
9. Lin T, Yan SG, Cai ZX, Ying ZM. Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials. Osteoporos Int. 2012;23:1823–34.
10. Gruen TA, McNeice GM, Amstutz HC. "Modes of failure" of cemented stem-type femoral components: a radiographic analysis of loosening. Clin Orthop Relat Res. 1979;141:17–27.
11. de Morton NA. The PEDro scale is a valid measure of the methodological quality of clinical trials: a demographic study. Aust J Physiother. 2009;55:129–33.
12. Iwamoto N, Inaba Y, Kobayashi N, Isihara T, Yukawa Y, Saito T. A comparison of the effects of alendronate and alfacalcidol on bone mineral density around the femoral implant and in the lumbar spine after total hip arthroplasty. J Bone Joint Surg Am. 2011;93:2103–9.
13. Skoldenberg OG, Salemyr MO, Boden HS, Ahl TE, Adolphson PY. The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial. J Bone Joint Surg Am. 2011;93:1857–64.
14. Yamagishi S, Masuhara K, Yamaguchi K, Nakai T, Fuji T, Seino Y. Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty. Osteoporos Int. 2007;18:1009–15.
15. Yamaguchi K, Masuhara K, Yamazaki S, Fuji T. Efficacy of different dosing schedules of etidronate for stress shielding after cementless total hip arthroplasty. J Orthop Sci. 2005;10:322–9.
16. Venersma PK, Kroger HP, Miettinen HJ, Junvelin JS, Suomalainen OT, Alhav EM. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study. J Bone Miner Res. 2001;16:2126–31.
17. Dohrmann C, Oktolini S, Romano P, Isaia G, Agnesi L, Dallat D, et al. Decreased peri-implant bone loss in patients treated with clodronate: a 1-year randomized controlled trial. Calcif Tissue Int. 2010;86:436–46.
18. Arambolgha M, Rittmeister M, Hennings T. Alendronate prevents femoral periprosthetic bone loss following total hip arthroplasty: prospective randomized double-blind study. J Orthop Res. 2006;24:1336–41.
19. Arambolgha M, Pilz M, Wazzecha J, Rauschmann M. Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty. J Orthop Res. 2009;27:183–8.
20. Hennings T, Arambolgha M, Schwarz A, Zichler L. Dose-dependent prevention of early periprosthetic bone loss by alendronate. Z Orthop Ihre Grenzgeb. 2002;140:42–7.
21. Mortatone M, Quarta E, Quarta L, Calcagnile F, Grimaldi A, Orgiani MA, et al. Alendronate and cementless total hip arthroplasty: densitometric measurement of periprosthetic bone mass and new therapeutic approach to the prevention of aseptic loosening. Clin Cases Miner Bone Metab. 2012;9:50–5.
22. Dominguez-Bartmss SN, Tandberg D, Cheema AM, Salay EA. Efficacy of alendronate in the treatment of low bone density in the pediatric and young adult population. J Bone Joint Surg Am. 2012;94:e662.
23. Friedrich G, Badr R, Sihren C, Rehak P, Agner R, Windhaber R. The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial. J Bone Joint Surg Am. 2009:91:274–81.
24. Prieto-Alhambra D, Javid MK, Judge A, Murray D, Carr A, Cooper C, et al. Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip joint: population based retrospective cohort study. BMJ. 2011;343:d7222.
25. Thillemann TM, Pedersen AB, Møhrner H, Johnsen SP, Soballe K. Postoperative use of bisphosphonates and risk of revision after primary total hip arthroplasty: a nationwide population-based study. Bone. 2011;46:946–51.
26. Sayyidmousavi A, Bougherasha H. Investigation of stress shielding around the Stryker Omnifit and Exeter periprosthetic hip implants using an irreversible thermodynamic-based model. J Biomed Mater Res B Appl Biomater. 2012;100:1416–24.
27. Boden HS, Skoldenberg OG, Salemyr MO, Lundberg HJ, Adolphson PY. Continuous bone loss around a tapered uncemented femoral stem: a long-term evaluation with DEXA. Acta Orthop. 2006;77:877–85.
28. Yeung E, Britt PT, Chana R, Jackson MP, Holloway I, Walter WL, et al. Mid-term results of third-generation alumina-on-alumina ceramic bearings in cementless total hip arthroplasty: a ten-year minimum follow-up. J Bone Joint Surg Am. 2012;94:138–44.
29. Eiberhardt C, Habermann B, Muller S, Schwarz M, Baus F, Kurth AH. The bisphosphonate ibandronate accelerates osseointegration of hydroxyapatite-coated cementless implants in an animal model. J Orthop Sci. 2007;12:611–6.
30. Colon-Emeric CS. Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis: enough of a good thing. JAMA. 2006;296:2968–9.